Dr. Reddy's partners with Senores Pharma to launch Ketorolac Tromethamine Tablets USP

25 May 2022 , 02:00 PM

Dr. Reddy’s Laboratories Ltd., announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market in partnership with Senores Pharmaceuticals, Inc.

The drug is approved by the U.S. Food and Drug Administration (USFDA).

The company stated in its press release, “Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug to cure the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following intravenous or intramuscular dosing of ketorolac tromethamine, if necessary.”

“We are thrilled about launch of this drug, and pleased with our partnership with Senores to create an affordable access to this product and to further expand our portfolio presence in the US market,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories.

“We are delighted to join hands with Dr. Reddy’s Laboratories for the launch of Ketorolac Tromethamine Tablets in the U.S. market,” commented Dhananjay Barot, Director of Senores Pharmaceuticals, Inc.

Dr Reddys Laboratories is currently trading at Rs4,332 down by Rs19.1 or 0.44% from its previous closing of Rs4,351.10 on the BSE. The scrip touched intraday high and low of Rs4,396.35 and Rs4,324.80 respectively.